Satellite Symposia

Satellite symposia are non-commercial, grant funded learning activities that are planned and conducted by the corporate community in conjunction with Nexus 2022. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.

Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.

Tuesday, Oct. 11, 2022| 2–4pm  

Advancements in Treatment Options for Age-Related Macular Degeneration and Diabetic Macular Edema, featuring a Patient Perspective| Location: National Harbor 2
  • Provider: Pharmacy Times Continuing Education™ 
  • This activity is supported by an educational grant from Genentech, a member of the Roche Group. 
  • Continuing education credit available for managed care pharmacists 
  • Contact hours: 1.5 

Program Description 

Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) affect 20 million and 21 million people globally, respectively, making them two of the most noteworthy causes of vision loss in adults worldwide. nAMD occurs when new or damaged blood vessels grow uncontrolled and lead to swelling in the macula. Similarly, DME is the result of blood vessels damaged by diabetic retinopathy leaking into the macula and causing swelling. Both diseases are complex and involve multiple pathways, primarily angiopoietin-2 (ANG-2) and vascular endothelial growth factor A (VEGF-A). Current treatments for both conditions inhibit VEGF, a protein that promotes blood vessel growth during periods of hypoxia. Though effective, anti-VEGF therapies pose a significant burden to patients, families, and healthcare providers due to the frequency of repeated injections, severe adverse effects, and potential tachyphylaxis. Emerging therapies aim to reduce these burdens through more effective and less frequent injections. This program will review the economic burden and reduced quality of life associated with nAMD and DME for patients, and present management and treatment selections for these diseases managed care professionals should be familiar with to improve patient adherence and outcomes. Clips from a patient perspective interview will be shown throughout this program to highlight the experience of a patient in accessing treatment and discussion of challenges faced in relation to therapy. 

Learning Objectives 

  • Examine limitations associated with traditional anti-vascular endothelial growth factor inhibitor treatments for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). 
  • Identify advantages of novel treatment/treatment approaches for nAMD and DME. 
  • Illustrate how managed care professionals can work with retinal specialists to promote optimal outcomes in nAMD and DME. 

Program Manager 

Kylie Ferrentino 
Pharmacy Times Continuing Education 
kferrentino@pharmacytimes.com 

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

Managed Care and Population Health Considerations in Modern Pneumococcal Vaccination: Moving the Needle on Infectious Outcomes| Location: National Harbor 2
  • Provider Med Learning Group
  • This activity is supported by an educational grant from Merck & Co., Inc. 
  • Continuing education credit available for this activity is designed to meet the educational needs of managed care practitioners as well as primary care physicians, nurse practitioners, pharmacists, and other members of the multidisciplinary team who evaluate patients for vaccination needs
  • Contact hours: 1.0 

Program Description 

This interactive, case-based program will explore the risk of pneumococcal infections from a population perspective. Through didactic discussion and case-based learning, this program aims to engage pharmacists and other health care professionals in understanding the importance and timing of pneumococcal vaccination, as well as the managed care implications. 

Learning Objectives

  • Evaluate the risk of pneumococcal infection from a population perspective and consider the importance of various serotypes in managed care considerations.
  • Assess clinical data and specific data with pneumococcal serotypes to contextualize treatment options in the context of guidelines.
  • Apply best practices for managed care in implementing pneumococcal vaccination schedules to improve health outcomes for members.

Program Manager 

Felecia Beachum
Med Learning Group
fbeachum@medlearninggroup.com 

Registration Link:  

https://www.medlearninggroup.com/cme-programming/pnv/

Tuesday, Oct. 11, 2022| 6–7:30pm

Evolving Management Options for Alopecia Areata: Clinical Burden, Cost Effective Care, and Emerging Treatments| Location: National Harbor 2
  • This CME activity for ACCME credit is provided by Integrity Continuing Education, Inc. This CE activity for ACPE credit is jointly provided by Global Education Group and Integrity Continuing Education, Inc. 
  • This activity is supported by an educational grant from Pfizer, Inc. 
  • This educational activity has been designed for community pharmacists, specialty pharmacists, and healthcare professionals in allergy, immunology, dermatology and managed care who manage patients with AA. 
  • Contact hours: 1.5 

Program Description 

The hair loss that occurs in patients with alopecia areata (AA) imposes a significant psychological burden on the over 300,000 US individuals affected by the disease each year. Traditionally, AA management has been limited to the off-label use of various treatments, many of which can be associated with significant side effects and often provide only limited relief. As understanding of AA pathophysiology has evolved, we have witnessed the development of a number of novel targeted therapies. Foremost among these are multiple JAK inhibitors, one of which has just been approved by the FDA. Join our esteemed clinician faculty for a review of the recently approved and emerging JAK inhibitor therapies for AA. Complemented with case-based learning and faculty roundtable discussions, this symposium is designed to help clinicians achieve better outcomes for their patients with AA.  

Learning Objectives 

  • Outline the pathophysiology and clinical burden of alopecia areata (AA)
  • Review clinical data on emerging agents for AA to determine their potential placement in the treatment landscape
  • Understand the pharmacoeconomic factors associated with emerging AA therapies 

Program Manager 

NyQwayah Brown 
Integrity Continuing Education, Inc. 
nbrown@integrityce.com 

Registration Link: 

 https://integrityce.com/Nexus2022  

Tuesday, Oct. 11, 2022| 6–8pm

Challenging the Treatment Paradigm for HER2-low Breast Cancer: Managed Care Perspectives| Location: National Harbor 3
  • Provider: Pharmacy Times Continuing Education
  • This activity is supported by educational grants from Daiichi Sankyo and AstraZeneca.
  • Continuing education credit available for managed care pharmacists
  • Contact hours: 1.5 

Program Description 

About 50% of all primary breast cancers show low-level expression of human epidermal growth factor receptor 2 (HER2). Until recently, little has been known about the prognostic value of low HER2 expression in metastatic breast cancer. Historically, HER2-targeted therapies were not effective in patients with HER2-low disease, so HER2-low was categorized and treated as HER2-negative. However, novel therapies are showing promise against HER2-low disease, prompting investigation into additional targeted treatment strategies. Predictive biomarkers are now essential in identifying HER2-low status and guiding treatment selection in specific patient populations. This program will discuss the safety and efficacy profiles of these novel therapies as well as biomarker testing. As the understanding of HER2-low breast cancer expands, managed care professionals must utilize the most current data to navigate the challenges of both diagnosing and treating this patient population. This program will examine the clinical impact of newly developed treatment strategies for patients with breast cancer with low HER2 expression, with a focus on implications for guideline recommendations and treatment pathways. 

Learning Objectives

  • Explore the utility of current biomarker testing requirements to identify patients with human epidermal growth factor receptor 2 (HER2)-low breast cancer.
  • Analyze the safety and efficacy profiles of novel therapies for treating patients with HER2-low breast cancer.
  • Identify the role of managed care in the evolving approach to diagnosing and treating HER2-low breast cancer. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com 

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

Wednesday, Oct. 12, 2022| 6–8am

Achieving Appropriate Access to High Quality Care for the Treatment of Primary Immunodeficiency| Location: National Harbor 10 
  • Provided by Impact Education, LLC, the Immune Deficiency Foundation and the Postgraduate Institute for Medicine 
  • Supported by CSL Behring 
  • CME/CNE/CPE Credit Available
  • Contact hours: 1.5 

Program Description 

Primary immunodeficiency (PI) affects >500,000 people in the United States, with a significant proportion of individuals with milder immune system defects suspected as not being formally diagnosed. The occult nature of PI symptoms and an overwhelming cache of potential differential diagnoses result in frequently delayed diagnoses and misdiagnoses, culminating in a lack of access to effective treatment and worsening outcomes. Rapid growth within PI's diagnostic and therapeutic space is coupled with distinctly higher claims among patients whose diagnosis and appropriate treatment are delayed. These challenges are compounded for managed care professionals managing rising healthcare expenditures and the specialty drug trend. By instituting applicable coverage criteria, these stakeholders can improve the recognition and management of PI within their plan populations and ultimately impact total costs. 

Learning Objectives

  • Describe the potential signs and symptoms of primary immunodeficiency (PI) in addition to predominant screening and diagnostic modalities
  • Assess available therapeutic options for PI based on disease type and patient characteristics
  • Characterize the adverse effect of excess cost-sharing on and prohibitive coverage criteria on patient access and adherence 
  • Implement medical and pharmacy benefit design strategies that improve access to therapy and manage costs with evidence-based clinical care for PI 

Program Manager 

Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net 

Registration Link:

www.impactedu.net/nexus2022   

Managed Care Approaches in Optimizing the Impact of PARP Inhibitors on Resource Utilization and Clinical Outcomes in Ovarian Cancer| Location: National Harbor 3
  • Provider: Pharmacy Times Continuing Education
  • This activity is supported by an educational grant from GlaxoSmithKline.
  • Continuing education credit available for managed care pharmacists
  • Contact hours: 1.5 

Program Description 

Ovarian cancer is the leading cause of death in patients diagnosed with gynecologic cancer in the United States. Despite debulking surgery and platinum-based chemotherapy, there is a high rate of recurrence in patients with advanced stage epithelial ovarian cancer. Poly (ADP-ribose) polymerase (PARP) inhibitors demonstrate efficacy as maintenance therapy following response to chemotherapy as well as in treatment of disease recurrence. Managed care pharmacists play a crucial role in appropriate utilization of PARP inhibitors, helping to direct guideline-driven, cost-effective treatment selection for patients with ovarian cancer. This program will explore the emerging role of PARP inhibitors for ovarian cancer and the differences among agents. Considerations for design of oncology clinical pathways and medication therapy management will also be discussed. 

Learning Objectives

  • Explore the nuances that differentiate the available PARP inhibitors that aid in guiding treatment selection.
  • Examine guideline recommendations and the clinical data for the role of PARP inhibitors in various stages of treatment for ovarian cancer.
  • Determine the cost of care and utilization management strategies to optimize the use of PARP inhibitors in the treatment of ovarian cancer. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

Wednesday, Oct. 12, 2022| 6–8pm 

Optimizing Solid Tumor Management with PARP Inhibition STRATEGIES FOR A CHANGING PARADIGM| Location: National Harbor 10
  • Provider Creative Educational Concepts, LLC 
  • Supported by AstraZeneca and Merck 
  • Continuing education credit available for oncology, specialty, and managed care pharmacists and physicians attending the 2022 Academy of Managed Care Pharmacy (AMCP) Nexus Annual Meeting 
  • Contact hours: 1.5 

Location

National Harbor 2/3

Program Description 

Activity attendees will gain an understanding of the role of the DNA damage response (DDR) pathway in solid tumor tumorigenesis and the latest guidelines and importance of genetic testing/counseling and related treatment recommendations; then they will be guided through an appraisal of current and emerging evidence for PARP inhibitors for solid tumor management. An expert-led discussion in transcending disparities in cancer care and improving equitable access will follow, as will a review of PARP inhibitor toxicity profiles and how to effectively anticipate, prevent, and manage adverse events that may arise. After the didactic portion of the presentation, an interactive case-based presentation will provide attendees an opportunity to apply what they have learned, with an emphasis on appropriate treatment selection, toxicity management, mitigation of modifiable health disparities, and promotion of patient adherence to oral oncolytic therapy. 

Learning Objectives 

  • Appraise current expert consensus guideline recommendations for managing solid tumor malignancies with PARP inhibitors, including evidence-based approaches for anticipating, mitigating, and managing adverse events. 
  • Evaluate the crucial importance of genetic testing/counseling when considering PARP inhibitor therapy for patients with solid tumors. 
  • Review emerging PARP inhibitor clinical trial data in both the treatment and maintenance settings for solid tumors and discuss how these agents continue to galvanize change across the disease management continuum 
  • Recognize healthcare disparities that result in inequitable access and identify approaches for overcoming these obstacles and improving outcomes for all patients. 
  • Use a case-based approach to develop practical strategies for appropriate treatment selection, toxicity management, mitigation of healthcare disparities and inequitable access to care, and promotion of patient adherence to PARP inhibitors and other oral oncolytics, with the express goal of improving outcomes across the solid tumor landscape. 

Program Manager 

Ashley Lilly, MPA 
Creative Educational Concepts, LLC 
lillya@ceconcepts.com 

Registration Link:  

https://www.ceconcepts.com/parp-2022 

Targeting the Sickle Cell Disease Cascade and the Shifting Approach to Care| Location: National Harbor 3
  • Provider: Pharmacy Times Continuing Education
  • This activity is supported by an educational grant from Global Blood Therapeutics.
  • Continuing education credit available for managed care pharmacists
  • Contact hours: 1.5 

Program Description 

Sickle cell disease (SCD) affects about 100,000 people in the United States, mostly African Americans and has a per-patient lifetime cost of $1 million. As efforts are made to improve the efficiency and accuracy in treating SCD, focus of care has shifted from symptomatic treatment towards disease modification. Hydroxyurea has been the mainstay of therapy for more than 2 decades and is a ribonucleotide inductase inhibitor that induces HbF levels. A newly approved drug, voxelotor, reduces polymerization of HbS, increases hemoglobin and disrupts the disease cascade. Crizanlizumab binds to P-selectin on the surface of platelets and endothelium in blood vessels and blocks its interaction with P-selectin glycoprotein ligand 1, which reduces adhesion and platelet and neutrophil aggregation. Disease-modifying therapies can reduce the development of end organ damage and complications of SCD, lessen the incidence of painful, chronic symptoms, as well as reduce hospitalizations, lengths of stay, emergency room use, and blood transfusions. This in turn reduces overall costs while increasing quality of life. This symposium will supply managed care professionals with critical knowledge on SCD, therapeutic options for both symptomatic treatment and disease modification, and methods for providing the best possible care for patients by reducing healthcare resource utilization and improving patient outcomes. Embedded throughout the program are animation videos showcasing the pathophysiology and mechanisms of action of SCD and emerging therapies. 

Learning Objectives

  • Illustrate the pathophysiology of sickle cell disease (SCD) cascade and the treatment challenges associated with the management of the disease and its comorbidities.
  • Differentiate between treatments for acute management and disease modification and interpret clinical trial data and real-world evidence that supports treatment.
  • Determine the cost of SCD and specific managed care strategies to maximize the efficiency of healthcare resource utilization while improving patient outcomes. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

Thursday, Oct. 13, 2022| 6–8am

Evaluating Novel Nonhormonal Approaches for the Treatment of Menopausal Vasomotor Symptoms| Location:National Harbor 3
  • Provider: Pharmacy Times Continuing Education™ 
  • This activity is supported by an educational grant from Astellas. 
  • Continuing education credit available for managed care pharmacists 
  • Contact hours: 1.5 

Program Description 

Menopause, the cessation of menstrual cycles, occurs for every woman, typically during their late 40s or 50s. This transition may have varying presentation of bothersome symptoms that affect quality of life, sleep pattern, and daily routine, which warrants an individualized approach to care. Among these challenges, 60% to 85% of women struggle most with vasomotor symptoms (VMS), with 30% experiencing severe VMS that can last between 7 and 10 years. There is substantial value in understanding the effects of menopause through VMS, and pharmacists should be able to assess VMS and understand the attributes of menopausal hormone therapy. There are several potential nonhormonal options, including fezolinetant and osanetant, selective neurokinin-3 receptor (NK3R) antagonists, and elinzanetant, a dual neurokinin-1,3 receptor antagonist. This program will explore resources and challenges managed care professionals should be aware of regarding VMS treatment as well as the significance of individualized care associated with menopause. 

Learning Objectives

  • Examine the health burden associated with vasomotor symptoms (VMS) in menopause and the risk/benefit profile for hormonal therapy.
  • Analyze the efficacy and safety data for investigational nonhormonal neurokinin-3 receptor (NK3R) antagonists and the dual neurokinin-1,3 receptor antagonists in the treatment and management of VMS.
  • Investigate the healthcare resource utilization and economic burdens associated with VMS and the need for a personalized approach in treatment selection. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary 

ROS1-Targeted Treatments in NSCLC: Updates and Best Practices for Managed Care| Location: National Harbor 10
  • Provider: Pharmacy Times Continuing Education™
  • This activity is supported by an educational grant from Turning Point Therapeutics.
  • Continuing education credit available for managed care pharmacists
  • Contact hours: 1.5

Program Description 

For multiple types of cancers, identification of biomarkers has an important role in determining treatment approach. ROS proto-oncogene 1 receptor tyrosine kinase (ROS1) rearrangements are observed in up to 2% of non-small cell lung cancers (NSCLCs) and generally are associated with a younger age and little to no history of smoking. Several tyrosine kinase inhibitors (TKIs) are approved or under investigation for treatment of patients with ROS1-rearranged NSCLC. Due to occurrence of resistance mechanisms, ROS1 TKI treatment strategies can be challenging to manage. Managed care professionals involved in the care of patients with ROS1-rearranged NSCLC must understand the latest clinical efficacy data, safety concerns, and how to monitor and address acquired TKI resistance to define best practices for molecular testing and utilization of targeted therapies in specific target populations. This program will focus on the latest developments in molecular testing as related to the use of targeted TKIs in the treatment of ROS1-rearranged NSCLC. 

Learning Objectives

  • Examine molecular testing and current treatment guidelines for ROS1-rearranged non-small cell lung cancer (NSCLC).
  • Differentiate among available and emerging tyrosine kinase inhibitors (TKIs) and the factors affecting treatment selection in the management of ROS1-rearranged NSCLC.
  • Explore the managed care approaches and best practices in optimizing the value of biomarker testing and treatment selection of TKIs in the management of ROS1-rearranged NSCLC. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com 

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

Thursday, Oct. 13, 2022| 6–8pm

BCMA-Targeted Therapies in Multiple Myeloma: What the Pharmacist Needs to Know| Location: National Harbor 10
  • Provider Vindico Medical Education is accredited through June 30, 2025 by the Accreditation
  • Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
  • This educational activity is supported by an educational grant from GlaxoSmithKline.
  • The intended audience for this activity is managed care pharmacists, oncology pharmacists, and other health care professionals involved in the management of patients with multiple myeloma.
  • Contact hours: 1.5 

Program Description 

Although the median overall survival rate for patients with multiple myeloma (MM) has nearly doubled during the last 2 decades, MM remains incurable, and a majority of patients develop relapsed disease. The prognosis is poor among these patients, with a median overall survival of just over 1 year after 3 lines of therapy. Although improvements in diagnosis, risk stratification, and treatment continue—with multiple agents now available from various drug classes—additional novel agents with improved efficacy and safety are still needed, particularly in the relapsed or refractory setting. Several therapies have recently been approved that target B-cell maturation antigen (BCMA), a transmembrane protein expressed by malignant plasma cells that is involved in plasma and B-cell survival, B-cell maturation and growth, and activation of regulatory T cells. In this activity, expert clinicians will review the current treatment guidelines and the most recent clinical data supporting the use of BCMA-targeted for relapsed/refractory MM, define the disease and clinical characteristics of patients for whom BCMA-targeted therapy is appropriate, and describe the optimal multidisciplinary care coordination strategies for the management of treatment-emergent adverse events in patients receiving BCMA-targeted therapies. 

Learning Objectives

  • Outline current guideline recommendations for the treatment of relapsed/refractory multiple myeloma.
  • Review the patient, disease, and treatment characteristics that may make patients likely to benefit from BCMA-targeted therapies.
  • Assess the latest clinical efficacy data and safety profiles for recently approved BCMA-targeted therapies for patients with relapsed/refractory multiple myeloma.
  • Define multidisciplinary care coordination strategies for the recognition and management of adverse events in patients receiving BCMA-targeted therapies. 

Program Manager 

Questions@VindicoCME.com 

Registration Link:  

https://vindicoCME101322.eventbrite.com/?aff=linkout 

Iron Deficiency: Managed Care Considerations for Optimizing Evidence-Based and Cost-Effective Use of IV Iron Replacement Therapies| Location: National Harbor 3
  • Provider ProCE 
  • Supported by American Regent 
  • This activity is intended for pharmacists, including managed care, specialty, and clinical pharmacists, who care for patients with iron deficiency, as well as pharmacy directors, chief pharmacy officers, and other stakeholders in pharmacy practice. 
  • Contact hours: 1.5 

Program Description 

Iron deficiency is often associated with chronic diseases, such as heart failure (HF), chronic kidney disease (CKD), and inflammatory bowel disease (IBD). This educational activity will review the role of IV iron replacement in iron deficiency and accompanying chronic conditions and focus on the economic burden of these diseases and the impact of IV iron on healthcare resource utilization. 

Learning Objectives 

  • Recognize the etiology, pathophysiology, and impact of iron deficiency in common comorbidities such as HF, CKD, and IBD 
  • Discuss efficacy and safety data regarding IV iron replacement therapies for the treatment of iron deficiency in concomitant chronic conditions, as well as recommended dosing and appropriate implementation of these agents 
  • Determine strategies to optimize access to appropriate patient-centered therapies and mitigate financial burdens to improve the management of iron deficiency and promote efficient healthcare resource utilization 

Program Manager 

Cara Blair 
ProCE 
cblair@clinicaloptions.com 

Registration Link:

https://bit.ly/3di2SaK 

Friday, October 14, 2022| 6–8am 

The Evolving Treatment Landscape for HR+/HER2- Breast Cancer: Updates and Considerations for Managed Care| Location: National Harbor 3
  • Provider: Pharmacy Times Continuing Education™
  • This activity is supported by an independent medical education grant from Sanofi.
  • Continuing education credit available for managed care pharmacists
  • Contact hours: 1.5 

Program Description 

Despite recent improvements in the treatment and management of breast cancer, the prognosis for patients is dependent on the stage and type of cancer. Hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) breast cancer accounts for 70% of all cases; while it is generally diagnosed in the early stage with favorable cure rates, the median overall survival for those diagnosed with advanced breast cancer is just 2 to 3 years. More targeted treatments, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, are being developed to combat advanced HR+/HER2- disease. This program will focus on recent clinical trial updates on the long-term efficacy and safety of CDK4/6 inhibitors and endocrine therapies in specific patient populations with advanced HR+/HER2- breast cancer. As quality of life is a central factor in the choice of treatments, the impact of adverse effect profiles of the CDK4/6 inhibitors is important for treatment selection and management of patients with advanced breast cancer. Additional considerations for managed care pharmacists on the multidisciplinary oncology care team to integrate treatment recommendations and proactively manage drug therapy while mitigating costs for patients and the healthcare system will be discussed. 

Learning Objectives 

  • Break down the pathogenesis of breast cancer, the guideline-recommended approach to care, and the treatment goals for patients with hormone receptor-positive (HR+) / human epidermal growth factor receptor 2-negative (HER2-) advanced and metastatic breast cancer.
  • Analyze the recent clinical data for the FDA-approved cyclin-dependent kinase (CDK) 4/6 inhibitors and novel endocrine therapies in the treatment of HR+/HER2- breast cancer.
  • Identify strategies to integrate recent clinical updates to treatment protocols for the management of HR+/HER2- metastatic breast cancer to optimize outcomes and healthcare resource utilization. 

Program Manager 

Kylie Ferrentino
Pharmacy Times Continuing Education
kferrentino@pharmacytimes.com 

Registration Link:  

https://event.pharmacytimes.org/event/ec03c534-7326-44af-b94c-1009f33ddf97/summary

For more information, please contact us.